Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 67 of 67 entries
View as:

Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL

Phase: N/A Priority: Normal
NCT ID: NCT02888977 Org: User:
Start: 12/31/12 End: 12/31/22 Due: 12/31/23

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

Phase: N/A Priority: Normal
NCT ID: NCT02896842 Org: User:
Start: 09/30/10 End: 12/31/16 Due: 12/31/17

Descriptive Study of Multiligamentary Reconstruction of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT03932838 Org: User:
Start: 12/01/17 End: 06/01/20 Due: 06/01/21

Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05050461 Org: User:
Start: 09/20/21 End: 08/20/22 Due: 08/20/23

Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)

Phase: N/A Priority: Normal
NCT ID: NCT04386512 Org: User:
Start: 05/15/20 End: 07/15/20 Due: 07/15/21

Creation of a Syncope Channel for Patients Admitted to the Emergency Department for Loss of Consciousness and Not Hospitalized: Etiological Predictivity (Before/After Study)

Phase: N/A Priority: Normal
NCT ID: NCT06503653 Org: User:
Start: 03/31/24 End: 12/31/25 Due: 12/31/26

Evaluation of the Analgesic Effect of Music Therapy in Critically Ill Patients During Potentially Painful Nursing Procedures: a Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT02883959 Org: User:
Start: 02/28/13 End: 10/31/16 Due: 10/31/17

Pioglityazone and Imatinib for CML Patients

Phase: N/A Priority: Normal
NCT ID: NCT02888964 Org: User:
Start: 12/31/09 End: 02/29/16 Due: 02/28/17

Tryptophan, Serotonin and Kynurenine in Septic Shock

Phase: N/A Priority: Normal
NCT ID: NCT00684736 Org: User:
Start: 06/30/04 End: 04/30/08 Due: 04/30/09

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Phase: N/A Priority: Normal
NCT ID: NCT03895671 Org: User:
Start: 06/19/19 End: 12/01/24 Due: 12/01/25

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

Phase: N/A Priority: Normal
NCT ID: NCT02473146 Org: User:
Start: 11/18/15 End: 09/07/23 Due: 09/07/24

Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections

Phase: N/A Priority: Normal
NCT ID: NCT01946750 Org: User:
Start: 12/31/12 End: 06/30/17 Due: 06/30/18

Health-related Quality of Life and Functional Impairments After Intensive Care Unit Discharge

Phase: N/A Priority: Normal
NCT ID: NCT05111522 Org: User:
Start: 01/01/23 End: 01/01/26 Due: 01/01/27

Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04374695 Org: User:
Start: 05/01/20 End: 07/01/20 Due: 07/01/21

Development and Validation of a Language Screening Test in Acute Right Hemispheric Strokes

Phase: N/A Priority: Normal
NCT ID: NCT03622606 Org: User:
Start: 09/25/18 End: 10/31/24 Due: 10/31/25

Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04641806 Org: User:
Start: 11/01/20 End: 11/01/20 Due: 11/01/21

A Study for Tyrosine Kinase Inhibitors Discontinuation

Phase: N/A Priority: Normal
NCT ID: NCT02897245 Org: User:
Start: 12/31/12 End: 12/31/22 Due: 12/31/23